You are viewing the site in preview mode
Skip to main content
| |
Negative
|
Weak
|
Moderate
|
P value
|
|---|
| |
n = 11
|
n = 7
|
n = 9
|
|---|
|
Age years (median)
|
62
|
67
|
67
|
0.44
|
|
Tumor size mm (median)
|
20
|
22
|
25
|
0.43
|
|
Tumor grade (NHG)
| | | |
0.28
|
|
I
|
2
|
1
|
3
| |
|
II
|
4
|
2
|
3
| |
|
III
|
5
|
4
|
2
| |
|
Mitotic index
| | | |
0.33
|
|
1
|
6
|
1
|
6
| |
|
2
|
0
|
2
|
1
| |
|
3
|
5
|
3
|
1
| |
|
ER (n = 31)
| | | |
0.25
|
|
Positive
|
9
|
7
|
8
| |
|
Negative
|
2
|
0
|
0
| |
|
PR (n = 31)
| | | |
0.27
|
|
Positive
|
9
|
5
|
7
| |
|
Negative
|
2
|
2
|
1
| |
|
HER2 (n = 30)
| | | |
0.56
|
|
0
|
3
|
1
|
2
| |
|
1+
|
3
|
1
|
4
| |
|
2+
|
2
|
4
|
1
| |
|
3+
|
3
|
1
|
1
| |
|
Ki67 index (n = 26)
| | | |
0.22
|
|
Low
|
5
|
3
|
6
| |
|
High
|
6
|
2
|
2
| |
|
HMGCR (n = 38)
| | | |
0.25
|
|
Negative
|
7
|
2
|
2
| |
|
Positive
|
4
|
4
|
6
| |
|
Serum lipid levels (median)
| | | | |
|
LDL pre-treatment
|
3.74
|
3.45
|
3.8
|
0.84
|
|
HDL pre-treatment
|
1.6
|
1.73
|
1.6
|
0.26
|
|
Cholesterol pre-treatment
|
6.2
|
5.55
|
6.1
|
0.67
|
|
Apolipoprotein B pre-treatment
|
1.01
|
0.95
|
1.17
|
0.22
|
|
Apolipoprotein A1 pre-treatment
|
1.78
|
1.66
|
1.58
|
0.06
|
|
LDL post-treatment
|
1.48
|
1.7
|
1.8
|
0.99
|
|
HDL post-treatment
|
1.63
|
1.64
|
1.5
|
0.41
|
|
Cholesterol post-treatment
|
4.1
|
3.5
|
3.4
|
0.43
|
|
Apolipoprotein B post-treatment
|
0.54
|
0.56
|
0.66
|
0.43
|
|
Apolipoprotein A1 post-treatment
|
1.71
|
1.51
|
1.54
|
0.19
|
- NHG Nottingham histologic grade I-III (post-treatment pathological report), mitotic index according to Nottingham criteria (post-treatment pathological report), baseline tumor data (pretreatment): Ki67 high if > 20%, HMGCR positive if any cytoplasmic staining, ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) P values: linear-by-linear association chi-square test
